Project Soraprazan - a new regenerative therapy for Stargardt's disease

Basic data

Title:
Soraprazan - a new regenerative therapy for Stargardt's disease
Duration:
01/12/2017 to 30/11/2021
Abstract / short description:
Abnormal accumulation of lipofuscin in the RPE cells is a hallmark in Stargardt's disease. As lipofuscin cannot be removed from the RPE cells in the eyes neither spontaneously nor with existing therapies, the accumulation of lipofuscin in the RPE cells of the eyes results in the degradation of the RPE cells and consequently in worsening of visual acuity and could lead to blindness. Soraprazan was able to show removal of lipofuscin in RPE cells. Aim of the phase II trial in this project is to evaluate savety and efficacy of orally taken Soraprazan treatment compared to placebo.
Keywords:
Lipofuszin
Sehverlust
Depigmentierung
Morbus Stargardt

Involved staff

Managers

Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Research Center for Ophthalmology
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine

Funders

Brüssel, Belgium
Help

will be deleted permanently. This cannot be undone.